Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02381301

Biomarkers and Cardiac CT

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.

One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Maastricht University Medical Center

Maastricht, Limburg, 6202AZ, Netherlands

Location status: Recruiting

Location contact

Bas L Kietselaer, MD, PhD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients referred from the Cardiology clinic for routine CCTA.

Exclusion criteria

  • Pregnancy
  • Severe renal insufficiency
  • Severe allergy to contrast medium
  • Inability to obtain informed consent
  • Age below 18 years

Treatment and study plan

Venous blood sampling prior to CCTA.

Biological

Primary outcomes

  1. Data registration of patients undergoing CCTA and given written informed consent.

    Time frame: 15 years.

  2. To detect these patients for cardiovascular disease and Long term CV outcome (MACE).

    Time frame: 15 years.

Secondary outcomes

  1. The relationship of novel blood biomarkers with CCTA findings.

    Time frame: 15 years.

  2. The predictive value of these biomarkers to predict CAD in patients undergoing CCTA.

    Time frame: 15 years.

  3. The prognostic value of these biomarkers (in combination) to predict MACE.

    Time frame: 15 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Bas Kietselaer, MD, PhD

CONTACT

[email protected]

+31433871587

Sibel Altintas, MD

CONTACT

[email protected]

+31433881232

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Registry information

Official study title

Biomarkers and Cardiac Computed Tomography: Relationship Between Cardiovascular Biomarkers and Coronary Artery Disease in Patients Undergoing Cardiac Computed Tomography

Important dates

Study start
2015
Primary completion
2029
Study completion
2029
First posted
Mar 6, 2015
Registry last updated
Mar 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.